Dengue Vaccine - Global Market Trajectory & Analytics

Global Dengue Vaccine Market to Reach US$962.1 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Dengue Vaccine estimated at US$340 Million in the year 2020, is projected to reach a revised size of US$962.1 Million by 2027, growing at a CAGR of 16% over the analysis period 2020-2027. Government Institutions, one of the segments analyzed in the report, is projected to grow at a 15.2% CAGR to reach US$490.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hospitals segment is readjusted to a revised 16.6% CAGR for the next 7-year period. This segment currently accounts for a 31.2% share of the global Dengue Vaccine market.

The U. S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 20.9% CAGR for the Period of 2020-2027

The Dengue Vaccine market in the U. S. is estimated at US$97.8 Million in the year 2020. The country currently accounts for a 28.77% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$193.1 Million in the year 2027 trailing a CAGR of 20.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 14.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR while Rest of European market (as defined in the study) will reach US$193.1 Million by the year 2027.

NGOs Segment Corners a 15.2% Share in 2020

In the global NGOs segment, USA, Canada, Japan, China and Europe will drive the 16.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$38.8 Million in the year 2020 will reach a projected size of US$113.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$152.3 Million by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period. We bring years of research experience to this 9th edition of our report. The 185-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Biological E. Ltd.
• GlaxoSmithKline plc
• Instituto Butantan
• Panacea Biotec Ltd.
• Sanofi SA
• Takeda Pharmaceuticals Company Ltd.
• Vabiotech